MRC (UKRI)
Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures R&D
Expression of interest deadline; full application opens 5 November 2026, closes 20 January 2027
Last updated:
Details
| Funder | MRC (UKRI) |
| Budget | Up to £4M (80% FEC) |
| Deadline | 20 October 2026 |
| Duration | Up to 30 months |
| Consortium | Optional — collaboration with UK industry partners and project partners encouraged but not a prerequisite for application |
| Application | 2-stage: mandatory expression of interest → full application (by invitation) |
| Frequency | One-off |
| Eligible countries | GB |
Eligibility & scope
Funding for pre-clinical and early translational R&D of medical countermeasures for CBRN threats, from prototype development through early-phase clinical studies (up to phase 2a). Applicant must be employed by a UK-based eligible research organisation; international and commercial organisations cannot lead or partner as project lead.
Related on Grantsby
- MRC (UKRI) writing tips & FAQ
Evaluation criteria, proposal structure, common mistakes.
Similar grants
Proof of Concept
MRC (UKRI)Deadline: 18 Nov 2026No limit stated; 80% FEC fundedMRC Proof of Concept
MRC (UKRI)Deadline: 4 Nov 2026No limit stated; 80% FEC funded (100% for permitted exceptions)Drug Development Project
Cancer Research UKTranslation MRC Impact Acceleration Awards
MRC (UKRI)Deadline: 11 Nov 2026£50k–£300k FEC (80% funded, i.e. up to £240k awarded)MRC Experimental Medicine
Medical Research Council (MRC)Deadline: 7 Oct 2026No limit stated; 80% of full economic cost funded
Browse Related
Could Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures R&D be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →